GRADE evidence profile

Quality assessment

№ of patients

Effect

Quality

Importance

№ of studies

Study design

Risk of bias

Inconsistency

Indirectness

Imprecision

Other considerations

plaatjesaggregatieremmers

placebo

Relative
(95% CI)

Absolute
(95% CI)

Mortaliteit (alle oorzaken) (follow up: range 6 months to 12 months)

6

randomised trials

not serious

not serious

Very serious

serious

none

71/1667 (4.3%)

56/987 (5.7%)

RR 0.77
(0.55 to 1.10)

13 fewer per 1000
(from 6 more to 26 fewer)

⨁⨁◯◯
LOW

CRITICAL

Cardiovasculaire mortaliteit (follow up: 12 months)

1

randomised trials

not serious

not serious

Very serious

very serious

none

4/203 (2.0%)

4/208 (1.9%)

RR 1.54
(0.44 to 5.37)

10 more per 1000
(from 11 fewer to 84 more)

⨁◯◯◯
VERY LOW

CRITICAL

Myocardinfarct (fataal en niet fataal) (follow up: range 6 months to 12 months)

6

randomised trials

not serious

not serious

very serious

not serious

none

155/1667 (9.3%)

106/987 (10.7%)

RR 0.86
(0.67 to 1.12)

15 fewer per 1000
(from 13 more to 35 fewer)

⨁⨁◯◯
LOW

CRITICAL

Herseninfarct (fataal en niet fataal) (follow up: 12 months)

1

randomised trials

not serious

not serious

Very serious

very serious

none

2/203 (1.0%)

4/208 (1.9%)

RR 0.51
(0.09 to 2.77)

9 fewer per 1000
(from 18 fewer to 34 more)

⨁◯◯◯
VERY LOW

CRITICAL

Hersenbloeding (follow up: range 6 months to 12 months)

4

randomised trials

not serious

not serious

Very serious

very serious

none

6/917 (0.7%)

4/520 (0.8%)

RR 0.93
(0.28 to 3.13)

1 fewer per 1000
(from 6 fewer to 16 more)

⨁◯◯◯
VERY LOW

CRITICAL

Grote bloeding (major bleeding) (follow up: range 6 months to 12 months)

7

randomised trials

not serious

not serious

very serious

serious

none

144/1943 (7.4%)

60/1277 (4.7%)

RR 1.50
(0.95 to 2.36)

23 more per 1000
(from 2 fewer to 64 more)

⨁⨁◯◯
LOW

CRITICAL

Kleine bloedingen (minor bleeding) (follow up: range 6 months to 12 months)

7

randomised trials

not serious

not serious

very serious

serious

none

357/1943 (18.4%)

216/1277 (16.9%)

RR 1.25
(0.93 to 1.68)

42 more per 1000
(from 12 fewer to 115 more)

⨁◯◯◯
VERY LOW

IMPORTANT

Eindstadium nierfalen - not reported

-

-

-

-

-

-

-

-

see comment

not estimable

see comment

-

CRITICAL